Effect of iron and ascorbate on uroporphyria in ascorbate-requiring mice as a model for porphyria cutanea tarda

Hepatology

Volumn 45, Issue 1, 2007, Pages 187-194

  Gorman, Nadia ^a,b   Zaharia, Adrian ^a,b   Trask, Heidi S ^a,b   Szakacs, Juliana G ^c   Jacobs, Nicholas J ^b   Jacobs, Judith M ^b   Balestra, Dominic ^b   Sinclair, Jacqueline F ^a,b   Sinclair, Peter R ^a,b  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3,3',4,4',5 PENTACHLOROBIPHENYL; AMINOLEVULINIC ACID; ASCORBIC ACID; CYTOCHROME P450 1A2; GULONOLACTONE OXIDASE; HEXACHLOROBENZENE; IRON; IRON DEXTRAN; MALONALDEHYDE; UROPORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME SYNTHESIS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL;

AMINOLEVULINIC ACID; ANIMALS; ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; CYTOCHROME P-450 CYP1A2; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; IRON; IRON-DEXTRAN COMPLEX; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; POLYCHLORINATED BIPHENYLS; PORPHYRIA CUTANEA TARDA; UROPORPHYRINS;

EID: 33846414661     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21474     Document Type: Article

References (25)

1. Elder GH. Porphyria cutanea tarda and related disorders. In: Kadish KM, Smith KM, Guilard R, editors. The Porphyrin Handbook II. Vol. 14. Boston Academic Press, 2003:62-97.
2. Brady JJ, Jackson HA, Roberts AG, Morgan RR, Whatley SD, Rowlands GL, et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 2000;115:868-874.
3. Tannapfel A, Stolzel U, Kostler E, Melz S, Richter M, Keim V, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch 2001;439:1-5.
4. Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002;47:419-426.
5. Sinclair PR, Gorman N, Dalton T, Walton HS, Bement WJ, Sinclair JF, et al. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cypla2(-/-) null mutant mice. Biochem J 1998;330:149-153.
6. Smith AG. Porphyria caused by chlorinated AH receptor ligands and associated mechanisms of liver injury and cancer. In: Kadish KM, Smith KM, Guilard R, editors. The Porphyrin Handbook II. Vol. 14. Boston Academic Press, 2003:169-210.
7. Sinclair PR, Gorman N, Walton HS, Bement WJ, Jacobs JM, Sinclair JF. Ascorbic acid inhibition of cytochrome P450-catalyzed uroporphyrin accumulation. Arch Biochem Biophys 1993;304:464-470.
8. Sinclair PR, Gorman N, Sinclair JF, Walton HS, Bement WJ, Lambrecht RW. Ascorbic acid inhibits chemically induced uroporphyria in ascorbate-requiring rats. HEPATOLOGY 1995;22:565-572.
9. Sinclair PR, Gorman N, Shedlofsky SI, Honsinger CP, Sinclair JF, Karagas MR, et al. Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med 1997;130:197-201.
10. Percy VA, Naidoo D, Joubert SM, Pegoraro RJ. Ascorbate status of patients with porphyria cutanea tarda symptomatica and its effect on porphyrin metabolism. S Afr J Med Sci 1975;40:185-196.
11. Maeda N, Hagihara H, Nakata Y, Hiller S, Wilder J, Reddick R. Aortic wall damage in mice unable to synthesize ascorbic acid. Proc Natl Acad Sce U S A 2000;97:841-846.
12. Mauzerall D, Granick S. The occurrence and determination of delta-amino-levulinic acid and porphobilinogen in urine. J Biol Chem 1956;219: 435-446.
13. Lambrecht RW, Jacobs JM, Sinclair PR, Sinclair JF. Inhibition of uroporphyrinogen decarboxylase activity. The role of cytochrome P450-mediated uroporphyrinogen oxidation. Biochem J 1990;269:437-441.
14. Sinclair PR, Bement WJ, Bonkovsky HL, Sinclair JF. Inhibition of uroporphyrinogen decarboxylase by halogenated biphenyls in chick hepatocyte cultures. Essential role for induction of cytochrome P-448. Biochem J 1984;222:737-748.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
16. Sinclair PR, Gorman N, Walton HS, Sinclair JF, Lee CA, Rifkind AB. Identification of CYP1A5 as the CYP1A enzyme mainly responsible for uroporphyrinogen oxidation induced by Ah receptor ligands in chicken liver and kidney. Drug Metab Dispos 1997;25:779-783.
17. Sinclair PR, Gorman N, Walton HS, Bement WJ, Sinclair JF, Gerhard GS, et al. Uroporphyria in Hfe mutant mice given 5-aminolevulinate: A new model of Fe-mediated porphyria cutanea tarda. HEPATOLOGY 2001; 33:406-412.
18. Wagner KR, Hua Y, de Courten-Myers GM, Broderick JP, Nishimura RN, Lu SY, et al. Tin-mesoporphyrin, a potent heme oxygenase inhibitor, for treatment of intracerebral hemorrhage: in vivo and in vitro studies. Cell Mol Biol 2000;46:597-608.
19. Standeven AM, Wetterhahn KE. Ascorbate is the principal reductant of chromium (IV) in rat liver and kidney ultrafiltrates. Carcinogenesis 1991; 12:1733-1737.
20. Gorman N, Ross KL, Walton HS, Bement WJ, Szakacs JG, Gerhard GS, et al. Uroporphyria in mice: Thresholds for hepatic CYP1A2 and iron. HEPATOLOGY 2002;35:912-921.
21. Wapnick AA, Lynch SR, Seftel HC, Charlton RW, Bothwell TH, Jowsey J. The effect of siderosis and ascorbic acid depletion on bone metabolism, with special reference to osteoporosis in the Bantu. Br J Nutr 1971;25:367-376.
22. Chen K, Suh J, Carr AC, Morrow JD, Zeind J, Frei B. Vitamin C suppresses oxidative lipid damage in vivo, even in the presence of iron overload. Am J Physiol Endocrinol Metab 2000;279:E1406-E1412.
23. Gerster H. High-dose vitamin C: a risk for persons with high iron stores? Int J Vitam Nutr Res 1999;69:67-82.
24. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J 1999;13:1007-1024.
25. Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 2005;81:736-745.